Ferring recalls Minirin nasal spray for patient safety

Pharma News: Ferring Pharmaceuticals is initiating a precautionary recall of all MINIRIN Nasal Spray (desmopressin acetate) batches following the detection of a low volume and out-of-specification results in desmopressin content in some vials.

MINIRIN Nasal Spray (desmopressin acetate) is indicated for diabetes insipidus, nocturnal enuresis and renal concentrating capacity.

During testing of a sample, supplied overseas, a nasal spray bottle containing a low volume has been observed and was found as out-of-specification for both desmopressin (up to 155% of the targeted amount) and benzalkonium chloride (up to 120% of the targeted amount) contents. This could potentially result in an overdose of desmopressin.

Retail pharmacies are advised to inspect stock immediately and quarantine affected stock to prevent further use. Pharmacies are advised to return stock on hand to their wholesalers.

No alternative stock of MINIRIN Nasal Spray is available currently.

Patients who are currently using MINIRIN Nasal Spray should consult their GP or specialist for advice on switching to an alternative wafer or tablet desmopressin formulation as MINIRIN Nasal Spray may be out of stock until supply can be reinstated.